Related Experiment Videos
Improved diabetic control enhances erythroid stem cell proliferation in vitro.
The Journal of Clinical Endocrinology and Metabolism
|June 1, 1985
Summary
Continuous subcutaneous insulin infusion (CSII) in type I diabetes patients significantly improves metabolic control. This therapy also markedly enhances the proliferation of erythroid stem cells in vitro.
Area of Science:
- Endocrinology
- Hematology
- Cell Biology
Background:
- Continuous subcutaneous insulin infusion (CSII) improves metabolic control and growth in type I diabetes.
- The effect of CSII on cellular proliferation, specifically erythroid progenitors, is not well understood.
Purpose of the Study:
- To investigate the impact of short-term CSII therapy on the in vitro proliferation of erythroid progenitor stem cells.
Main Methods:
- A clonal stem cell assay was used to measure burst-forming units-erythroid (BFU-E) proliferation in peripheral blood.
- Eight patients with type I diabetes were studied before and after one week of CSII.
Main Results:
- CSII significantly improved metabolic control, reducing mean 24-h plasma glucose and increasing Somatomedin-C levels.
- The number of BFU-E colonies, indicative of erythroid progenitor proliferation, increased by 300% after one week of CSII.
Conclusions:
- Acute improvements in metabolic and hormonal status with CSII are associated with a significant increase in erythroid stem cell proliferation.
- CSII therapy may have a direct positive impact on hematopoietic stem cell function in patients with type I diabetes.